NP-delivered intervention fails to reduce early symptom burden during chemo
the ONA take:
A nurse practitioner (NP)-delivered symptom management intervention did not appear to reduce symptom burden compared with standard care among patients initiating chemotherapy for nonmetastatic cancer, a new study published in the journal Cancer has shown.
For the study, researchers sought to determine whether an NP-delivered symptom management intervention would reduce patient-reported symptom burden among patients initiating chemotherapy for nonmetastatic cancer.
Researchers enrolled 120 patients with nonmetastatic breast, colorectal, or lung cancer and randomly assigned them to receive standard care alone or standard care plus the intervention.
Patients assigned to the intervention group received telephone calls from their oncology NP during the week after each of the first two visits for chemotherapy administration.
Results showed that 50.8% of patients reported at least one physical symptom at the time of the first chemotherapy administration visit. Researchers found that the number of symptoms, symptom distress, and satisfaction with care increased, while the risk for anxiety symptoms decreased.
The likelihood of depression symptoms did not change over time. There was no difference in the reduction of patient-reported symptom burden between the two arms.
The findings suggest that it is important to continue identifying strategies to improve symptom management, particularly early symptoms, during chemotherapy for patients with nonmetastatic disease.
A nurse practitioner-delivered symptom management intervention did not appear to reduce symptom burden.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|